Perfecting the Power of
Antibody Therapeutics
Sound Biologics develops innovative antibody therapeutics for cancer, immune-mediated and inflammatory diseases, and neurological disorders. Leveraging our proprietary MabPair and bispecific antibody platforms, we aim to address complex disease biology and advance differentiated biologics that improve treatment options for patients.
Perfecting the Power of
Antibody Therapeutics
Sound Biologics develops innovative antibody therapeutics for cancer, immune-mediated and inflammatory diseases, and neurological disorders. Leveraging our proprietary MabPair and bispecific antibody platforms, we aim to address complex disease biology and advance differentiated biologics that improve treatment options for patients.
Perfecting the Power
of Antibody Therapeutics
Sound Biologics develops innovative antibody therapeutics for cancer, immune-mediated and inflammatory diseases, and neurological disorders. Leveraging our proprietary MabPair and bispecific antibody platforms, we aim to address complex disease biology and advance differentiated biologics that improve treatment options for patients.
Perfecting the Power of
Antibody Therapeutics
Sound Biologics develops innovative antibody therapeutics for cancer, immune-mediated and inflammatory diseases, and neurological disorders. Leveraging our proprietary MabPair and bispecific antibody platforms, we aim to address complex disease biology and advance differentiated biologics that improve treatment options for patients.
Perfecting the Power of
Antibody Therapeutics
Sound Biologics develops innovative antibody therapeutics for cancer, immune-mediated and inflammatory diseases, and neurological disorders. Leveraging our proprietary MabPair and bispecific antibody platforms, we aim to address complex disease biology and advance differentiated biologics that improve treatment options for patients.
Perfecting the Power
of Antibody Therapeutics
Sound Biologics develops innovative antibody therapeutics for cancer, immune-mediated and inflammatory diseases, and neurological disorders. Leveraging our proprietary MabPair and bispecific antibody platforms, we aim to address complex disease biology and advance differentiated biologics that improve treatment options for patients.
Innovation in Action
Innovation in Action
Complex diseases are driven by interconnected biological pathways, and targeting a single receptor or pathway may not provide optimal therapeutic benefit. Simultaneously engaging multiple targets or pathways offers the potential to address disease biology more effectively.
Complex diseases are driven by interconnected biological pathways, and targeting a single receptor or pathway may not provide optimal therapeutic benefit. Simultaneously engaging multiple targets or pathways offers the potential to address disease biology more effectively.
Sound Biologics develops innovative monoclonal antibody technologies designed to enable multi-target intervention through a single therapeutic product. Our complementary MabPair and bispecific antibody platforms provide distinct approaches to developing differentiated antibody therapeutics for complex diseases.
Sound Biologics develops innovative monoclonal antibody technologies designed to enable multi-target intervention through a single therapeutic product. Our complementary MabPair and bispecific antibody platforms provide distinct approaches to developing differentiated antibody therapeutics for complex diseases.
Explore Our Science ➤
Explore Our Science ➤
Innovation in Action
Complex diseases are driven by interconnected biological pathways, and targeting a single receptor or pathway may not provide optimal therapeutic benefit. Simultaneously engaging multiple targets or pathways offers the potential to address disease biology more effectively.
Sound Biologics develops innovative monoclonal antibody technologies designed to enable multi-target intervention through a single therapeutic product. Our complementary MabPair and bispecific antibody platforms provide distinct approaches to developing differentiated antibody therapeutics for complex diseases.
Explore Our Science ➤
Technology Platforms
MabPair Platform
Our proprietary MabPair Platform enables the production of two distinct, full-length antibodies as a single therapeutic product, supporting flexible antibody combinations designed to target multiple disease pathways.
Explore MabPair ➤
Bispecific Platform
Our proprietary Bispecific Platform enables the engineering of stable heterodimeric antibodies that combine two distinct binding specificities within a single molecule, supporting innovative therapeutic approaches targeting multiple disease pathways.
Explore Bispecific ➤
Technology Platforms
MabPair Platform
Our proprietary MabPair Platform enables the production of two distinct, full-length antibodies as a single therapeutic product, supporting flexible antibody combinations designed to target multiple disease pathways.
Explore MabPair ➤
Bispecific Platform
Our proprietary Bispecific Platform enables the engineering of stable heterodimeric antibodies that combine two distinct binding specificities within a single molecule, supporting innovative therapeutic approaches targeting multiple disease pathways.
Explore Bispecific ➤
Technology Platforms
MabPair Platform
Our proprietary MabPair Platform enables the production of two distinct, full-length antibodies as a single therapeutic product, supporting flexible antibody combinations designed to target multiple disease pathways.
Explore MabPair ➤
Bispecific Platform
Our proprietary Bispecific Platform enables the engineering of stable heterodimeric antibodies that combine two distinct binding specificities within a single molecule, supporting innovative therapeutic approaches targeting multiple disease pathways.
Explore Bispecific ➤
From Platforms to Therapeutic Programs
From Platforms to Therapeutic Programs
From Platforms to Therapeutic Programs
Our antibody engineering platforms support therapeutic programs across multiple areas of high unmet medical need.
Our antibody engineering platforms support therapeutic programs across multiple areas of high unmet medical need.
Our antibody engineering platforms support therapeutic programs across multiple areas of high unmet medical need.
Oncology
Antibody-based approaches targeting tumor biology and the immune microenvironment.
Immunology & Inflammation
Multi-pathway biologics designed to address complex inflammatory disease mechanisms.
Neurology
Next-generation antibody technologies designed to extend biologic therapeutics into CNS disease.
Oncology
Antibody-based approaches targeting tumor biology and the immune microenvironment.
Immunology & Inflammation
Multi-pathway biologics designed to address complex inflammatory disease mechanisms.
Neurology
Next-generation antibody technologies designed to extend biologic therapeutics into CNS disease.
Oncology
Antibody-based approaches targeting tumor biology and the immune microenvironment.
Immunology & Inflammation
Multi-pathway biologics designed to address complex inflammatory disease mechanisms.
Neurology
Next-generation antibody technologies designed to extend biologic therapeutics into CNS disease.
Explore Our Pipeline ➤
Explore Our Pipeline ➤
Explore Our Pipeline ➤
Leadership
Leadership
Leadership
Experienced scientists advancing antibody therapeutics from discovery through development.
Experienced scientists advancing antibody therapeutics from discovery through development.
Experienced scientists advancing antibody therapeutics from discovery through development.
Our leadership team brings extensive experience in antibody engineering, immuno-oncology, CMC development and regulatory submissions, with experience advancing biologic therapies from discovery to patients.
Our leadership team brings extensive experience in antibody engineering, immuno-oncology, CMC development and regulatory submissions, with experience advancing biologic therapies from discovery to patients.
Our leadership team brings extensive experience in antibody engineering, immuno-oncology, CMC development and regulatory submissions, with experience advancing biologic therapies from discovery to patients.
Explore Leadership ➤
Explore Leadership ➤
Explore Leadership ➤
Latest News
Latest News
Latest News
November 7, 2025
Sound Biologics Announces FDA Clearance of IND Application for QLP3119
November 7, 2025
Sound Biologics Announces FDA Clearance of IND Application for QLP3119
November 7, 2025
Sound Biologics Announces FDA Clearance of IND Application for QLP3119
Read More ➤
Read More ➤
Read More ➤
October 16, 2024
Sound Biologics Announces Breakthrough Approval of PSB205 by the National Medical Products Administration in China
October 16, 2024
Sound Biologics Announces Breakthrough Approval of PSB205 by the National Medical Products Administration in China
October 16, 2024
Sound Biologics Announces Breakthrough Approval of PSB205 by the National Medical Products Administration in China
Read More ➤
Read More ➤
Read More ➤
View All News ➤
View All News ➤
View All News ➤
At Sound Biologics, we bring together talented scientists and professionals committed to developing innovative biologic therapeutics for patients.
At Sound Biologics, we bring together talented scientists and professionals committed to developing innovative biologic therapeutics for patients.
Join us in advancing the next generation of antibody therapeutics.
Join us in advancing the next generation of antibody therapeutics.
Careers
Careers
Explore Careers ➤
Explore Careers ➤
Explore Careers ➤
At Sound Biologics, we bring together talented scientists and professionals committed to developing innovative biologic therapeutics for patients.
Join us in advancing the next generation of antibody therapeutics.
Join us in advancing the next generation of antibody therapeutics.
Careers
© 2026 Sound Biologics. All rights reserved. | |
© 2026 Sound Biologics. All rights reserved. | |
Privacy Policy
Privacy Policy
Terms of Use
Terms of Use
Google Map ➤
Google Map ➤
21720 23rd Dr SE
Bothell, WA 98021, USA
(425) 398-2323
21720 23rd Dr SE
Bothell, WA 98021, USA
(425) 398-2323
